+

SG11201405578TA - Pharmaceutical composition containing peptide - Google Patents

Pharmaceutical composition containing peptide

Info

Publication number
SG11201405578TA
SG11201405578TA SG11201405578TA SG11201405578TA SG11201405578TA SG 11201405578T A SG11201405578T A SG 11201405578TA SG 11201405578T A SG11201405578T A SG 11201405578TA SG 11201405578T A SG11201405578T A SG 11201405578TA SG 11201405578T A SG11201405578T A SG 11201405578TA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
composition containing
containing peptide
peptide
pharmaceutical
Prior art date
Application number
SG11201405578TA
Inventor
Takeo HIMI
Takeshi Watanabe
Toshihiro Nogami
Masami Sakai
Yukino WATANABE
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of SG11201405578TA publication Critical patent/SG11201405578TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201405578TA 2012-03-09 2013-03-08 Pharmaceutical composition containing peptide SG11201405578TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012072352 2012-03-09
PCT/JP2013/056429 WO2013133405A1 (en) 2012-03-09 2013-03-08 Pharmaceutical composition containing peptide

Publications (1)

Publication Number Publication Date
SG11201405578TA true SG11201405578TA (en) 2014-11-27

Family

ID=49116873

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405578TA SG11201405578TA (en) 2012-03-09 2013-03-08 Pharmaceutical composition containing peptide

Country Status (7)

Country Link
US (1) US20150359864A1 (en)
EP (1) EP2823824A4 (en)
JP (1) JP6159996B2 (en)
KR (1) KR20140138900A (en)
CN (1) CN104168917A (en)
SG (1) SG11201405578TA (en)
WO (1) WO2013133405A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP6740127B2 (en) * 2013-12-06 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド Formulation for neoplastic vaccine
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
CN112972378A (en) * 2014-09-24 2021-06-18 艾瑞朗医疗公司 Peptidomimetic macrocycles and formulations thereof
JP6781508B2 (en) * 2014-11-18 2020-11-04 塩野義製薬株式会社 Stabilized peptide composition
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018212358A1 (en) * 2017-05-19 2018-11-22 学校法人慶應義塾 Peptide vaccine and peptide vaccine composition for cranial nerve disease

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4689833B2 (en) * 1998-12-22 2011-05-25 イーライ リリー アンド カンパニー Storage-stable formulation of glucagon-like peptide-1
PT1513934E (en) 2002-06-06 2011-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colon cancers
JP4406607B2 (en) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 Peptide and pharmaceutical containing the same
EP2267022B1 (en) 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
PT1620456E (en) * 2003-04-18 2014-04-15 Biotech Synergy Inc TUMOR-ASSOCIATED HLA-A2 ANTIGENIC PEPTIDES AND THEIR COMPOSITIONS
WO2006090810A2 (en) * 2005-02-25 2006-08-31 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
PL1855707T3 (en) * 2005-02-28 2012-08-31 Oncotherapy Science Inc Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
BRPI0613970B8 (en) 2005-07-27 2021-05-25 Oncotherapy Science Inc composition for the treatment or prevention of colon cancer comprises a pharmaceutically effective amount of a sirna against a 34-tone polynucleotide
AU2006277295B2 (en) 2005-08-09 2011-08-11 Oncotherapy Science, Inc. Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same
CN101108869B (en) * 2006-07-21 2010-06-02 海南德泽药物研究有限公司 Mangiferin salt and method of preparing the same and use thereof
CA2667030C (en) * 2006-10-17 2016-03-15 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
JP2008127283A (en) * 2006-11-16 2008-06-05 Biseibutsu Kagaku Kenkyusho:Kk Feline infectious peritonitis vaccine
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
TWI438207B (en) * 2007-02-21 2014-05-21 Oncotherapy Science Inc Peptide vaccine for cancers exhibiting tumor-associated antigens
MX2009012964A (en) * 2007-06-01 2010-01-14 Acologix Inc High temperature stable peptide formulation.
CN101835792B (en) 2007-08-20 2015-04-15 肿瘤疗法科学股份有限公司 FOXM1 peptides and agents comprising FOXM1 peptides
WO2009025117A1 (en) 2007-08-20 2009-02-26 Oncotherapy Science, Inc. Cdca1 peptide and pharmaceutical agent comprising the same
WO2009131995A1 (en) * 2008-04-21 2009-10-29 Nanobio Corporation Nanoemulsion influenza vaccine
DE602008000891D1 (en) * 2008-04-30 2010-05-12 Immatics Biotechnologies Gmbh Novel formulations of tumor-associated peptides which bind to human leukocyte antigens of class I or II for vaccination
TW201000119A (en) 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
TWI526219B (en) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1 epitope peptides and vaccines containing the same
TWI466680B (en) 2008-08-01 2015-01-01 Oncotherapy Science Inc MELK epitope peptide and vaccine containing the peptide
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CN102264897B (en) 2008-10-22 2014-06-11 肿瘤疗法科学股份有限公司 RAB6KIFL/KIF20A epitope peptide and vaccine comprising it
TWI500932B (en) 2008-12-05 2015-09-21 Oncotherapy Science Inc WDRPUH epitope peptide and vaccine containing the peptide
TW201032820A (en) 2008-12-16 2010-09-16 Oncotherapy Science Inc ELOVL7 epitope peptides and vaccines containing the same
MX2011006755A (en) 2008-12-24 2011-07-20 Oncotherapy Science Inc C1orf59 peptides and vaccines including the same.
TWI469791B (en) 2009-02-18 2015-01-21 Oncotherapy Science Inc Foxm1 peptides and vaccines containing the same
JP2012519470A (en) 2009-03-04 2012-08-30 オンコセラピー・サイエンス株式会社 VANGL1 peptide and vaccine containing the same
WO2010106770A1 (en) 2009-03-18 2010-09-23 Oncotherapy Science, Inc. Neil3 peptides and vaccines including the same
TW201124530A (en) 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
TWI485245B (en) 2010-01-25 2015-05-21 Oncotherapy Science Inc Modified MELK peptide and vaccine containing the same
CA2857502C (en) * 2011-11-30 2019-08-13 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same

Also Published As

Publication number Publication date
WO2013133405A1 (en) 2013-09-12
CN104168917A (en) 2014-11-26
KR20140138900A (en) 2014-12-04
EP2823824A4 (en) 2015-09-16
JP2013213031A (en) 2013-10-17
JP6159996B2 (en) 2017-07-12
EP2823824A1 (en) 2015-01-14
US20150359864A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
AP3864A (en) Pharmaceutical composition
PL3181122T3 (en) Dasatinib pharmaceutical composition
ZA201501930B (en) Pharmaceutical composition
ZA201503594B (en) Pharmaceutical compositions
GB201118232D0 (en) Pharmaceutical composition
SG11201405578TA (en) Pharmaceutical composition containing peptide
EP2832730A4 (en) Mirabegron-containing pharmaceutical composition
IL266415A (en) Novel pharmaceutical composition
PT2815752T (en) Oral pharmaceutical composition
ZA201308157B (en) Pharmaceutical composition
EP2727593A4 (en) Nicorandil-containing pharmaceutical composition
EP2711010A4 (en) Pharmaceutical composition
ZA201502987B (en) Pharmaceutical composition
SI2638894T1 (en) Pharmaceutical composition containing phospholipid
HUP1100444A2 (en) Pharmaceutical composition
GB201211153D0 (en) Pharmaceutical compositions
HUP1100445A2 (en) Pharmaceutical composition
ZA201406407B (en) Pharmaceutical formulation containing flupirtin
ZA201400751B (en) Pharmaceutical composition
IL238075A0 (en) Pharmaceutical compositions
GB201221130D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition
GB201207701D0 (en) New pharmaceutical composition
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载